NFCR/Altru NYC Oncology Conference

October 30-31, 2018 | New York City



CONFERENCE SERIES SPONSORS

Cooley LLP

WSGR Wilson Sonsini Goodrich & Rosati PROFESSIONAL CORPORATION

VENABLE LLP

TORREYA

ALTRU INSTITUTE

NATIONAL FOUNDATION FOR CANCER RESEARCH
Research for a Cure

BIDEN CANCER INITIATIVE

onemedmarket
The Marketplace for Builders & Financiers

Mass Innovation Labs

October 30 Agenda

8:00 AM	BREAKFAST
9:00 AM	**Dr. Sujuan Ba, President of National Foundation for Cancer Research** **Update on NFCR Grant Funding, Investing and GBM Agile**
9:30 AM	**Panel - Developments in Cancer Diagnostics**
10:00 AM	Corporate Presentation - OTraces
10:25 AM	Corporate Presentation - Veriskin
10:50 AM	Corporate Presentation - Aethlon Medical
11:15 AM	Corporate Presentation - Cambium Oncology
11:40 PM	Corporate Presentation - GLADiator Biosciense s
12:05 PM	Corporate Presentation - Alpha Cancer
12:30 PM	Corporate Presentation - Oncolize
1:00 PM	**LUNCH KEYNOTE - Marty Tannenbaum, Founder, Cancer Commons and xCures Inc.** **Can AI Cure Cancer?**
2:00 PM	Corporate Presentation - Apricity Health
2:25 PM	Corporate Presentation - NuView Life Sciences
2:50 PM	**Panel - Application of Big Data and AI to Cancer**
3:30 PM	Corporate Presentation - Immunomic
3:55 PM	Corporate Presentation - LLTech
4:20 PM	Corporate Presentation - Genomic Expression
4:45 PM	Corporate Presentation - Aphios
5:10 PM	Corporate Presentation - SageMedic
5:35 PM	Corporate Presentation - Immix
6:00 PM	Corporate Presentation - Allevi
6:25 PM	Corporate Presentation - Flag Therapeutics
6:45 PM	**Reception - Food & Drinks**

SPEAKER BIOGRAPHIES



Greg Simon - President, Biden Initative

Greg Simon served as the Executive Director of the White House Cancer Moonshot Task Force, a position created by President Barack Obama and for which he was chosen by Vice President Joe Biden in March 2016. Over nine months, Greg and his team helped launch over seventy innovative collaborations. Greg returned to the White House after serving as Vice President Al Gore's Chief Domestic Policy Advisor between 1993 and 1997.

Greg was the CEO of Poliwogg, a financial services company creating unique capital market opportunities in healthcare and life sciences. Previously, he was Senior Vice President for Worldwide Policy and Patient Engagement at Pfizer, co-founded with Michael Milken, FasterCures/ The Center for Accelerating Medical solutions, and with Leon and Debra Black co-founded the Melanoma Research Alliance. Greg is a cancer survivor, having been recently successfully treated for chronic lymphocytic leukemia.

Amir Jafri—Former CTO/R&D Head, Cardinal Health

Amir Jafri is the founder of Immunicom and has served as its President and Chief Executive Officer since the company's inception in 2013. Amir has over 25 years of experience in healthcare technology and devices. As a senior executive in Fortune 50 companies and his own startups, he has managed multi-billion-dollar products on a global basis and is highly experienced with global regulatory environments. He was COO at West Health Institute; VP/CTO, VP R&D and VP Operations at Cardinal Health managing products with $1B in annual revenue (NYSE: CAH); VP/General Manager Healthcare Division at Manpower Group, responsible for the healthcare practice nationwide across 35 locations (NYSE: MAN). Prior to joining Manpower, Amir founded various healthcare startups that were subsequently acquired. He has successfully managed global businesses and has a track record of success in every business he has led. Amir serves on the Board of various healthcare technology startup companies and non-profit organizations. Amir received his Bachelors of Science Degree from Houston Baptist University with a double major in Chemistry and Biology and a minor in History. He attended medical school at the University of Texas.

October 31 Agenda

8:00 AM	BREAKFAST
9:00 AM	**Keynote - Greg Simon, President of the Biden Cancer Initiative**
9:30 AM	**<u>Therapeutics Panel - Developments in T-Cell & Gene Editing</u>** **Alfred Slanetz (Frm CEO Bluebird Bio) | Amir Jafri (Frm R&D Head Cardinal Health)** **William Ho (CEO Incysus) | Deepu Madduri (Head of CAR-T Clinic at Mount Sinai)**
10:00 AM	Corporate Presentation - Oxford BioTherapeutics
10:25 AM	Corporate Presentation - SciTech Development LLC
10:50 AM	Corporate Presentation - Zomanex
11:15 AM	Corporate Presentation - Lumicell
11:40 PM	Corporate Presentation - Can Fite Biopharma
12:05 PM	Corporate Presentation - SignPost Cancer Dx
12:30 PM	Corporate Presentation - Incysus
1:00 PM	**LUNCH KEYNOTE - Dennis Purcell—Founder, Aisling Capital**
2:00 PM	Corporate Presentation - SynDevRx
2:25 PM	Corporate Presentation - Immunicom
2:50 PM	Corporate Presentation - ImmunSys
3:15 PM	Corporate Presentation - Capella
3:40 PM	**<u>Venture Panel - Oncology Venture Investing Trends and Landscape</u>** **Dennis Purcell (Founder Aisling Capital) | John Friedman (Founder Easton Capital & Gore Range Capital) | Ken LaMontagne (Head of TAP Venture Program at the Leukemia and Lymphoma Society)**
4:20 PM	Corporate Presentation - Geneius
4:45 PM	Corporate Presentation - Concarlo
5:10 PM	Corporate Presentation - Sonify

SPEAKER BIOGRAPHIES

Marty Tenenbaum—Cancer Commons

Marty Tenenbaum is a renowned computer scientist, Internet entrepreneur and cancer warrior. He founded Cancer Commons and CollabRx (NASD: CRLX) to help each cancer patient obtain the best possible outcome. He was an Internet commerce pioneer, having founded or co-founded Enterprise Integration Technologies (1990, acquired by VeriFone), CommerceNet (1994), Veo Systems (1996, acquired by Commerce One), and Webify Solutions (2002, acquired by to IBM). He also served as an officer and Director of Medstory (acquired by Microsoft). Earlier in his career, Dr. Tenenbaum was a prominent AI researcher and led AI research groups at SRI International and Schlumberger Ltd.

Dr. Tenenbaum is a fellow and former board member of the American Association for Artificial Intelligence. He was also a Director of the Public Library of Science and a consulting professor of Computer Science at Stanford. He currently serves as a director of CommerceNet, Efficient Finance, Patients Like Me, and the Public Library of Science. His work on behalf of melanoma patients has been honored with the Melanoma Research Foundation's Legends for a Cure Humanitarian Award and the Society for Melanoma Research's Advocate for Progress Award. Dr. Tenenbaum holds B.S. and M.S. degrees in Electrical Engineering from MIT, and a Ph.D. from Stanford.

SPEAKER BIOGRAPHIES



Denis Purcell

Mr. Purcell is the original Founder of Aisling Capital LLC and currently serves as a Senior Advisor to Aisling. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, "H&Q") for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

Mr. Purcell is a frequent commentator on the industry and has been honored in the "Biotech Hall of Fame" by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.

Mr. Purcell has served as a director of Aton Pharma, Bridge Pharmaceuticals, Cengent Therapeutics, Dynova Laboratories, Paratek Pharmaceuticals, Valentis and Xanodyne Pharmaceuticals. He has served as a member of the Advisory Council at Harvard Medical School, the Board of Directors of the Biotechnology Industry Association, as well as the New York Biotechnology Association, the Irvington Institute and on the Board of L.E.K. Consulting. He currently sits on the board of Real Endpoints, Summus Global, Inc., Life Science Leader Magazine –Editorial Advisory Board, NY BIO Association and is a member of The University of Delaware Investment Visiting Committee Member.

SPEAKER BIOGRAPHIES

Dr. Sujuan Ba

Dr. Ba is the President and Chief Operating Officer of the National Foundation for Cancer Research (NFCR) and is recognized as one of the "Top 300 Women Leaders in Global Health" by the Global Health Programme at the Graduate Institute of International and Development Studies. Dr. Ba oversees NFCR's strategic directions for fundraising, financial planing, scientific direction and partnership development. Dr. Ba lead the establishment of NFCR's annual Szent-Györgyi Prize for Progress in Cancer Research, an international prize in recognition of outstanding scientific achievement in the war against cancer. She has served continuously for the past 12 years as co-chair of the Prize Selection Committee which consists of leaders in academic and pharmaceutical sectors. Dr. Ba also founded the Asian Fund for Cancer Research (AFCR), a non-profit organization headquartered in Hong Kong. As CEO of AFCR, Dr. Ba oversees the fund's collaborative research initiatives and public prevention programs in Hong Kong, Greater China, and throughout Asia.

Dr. Ba currently serves on the executive committee and Co-Chair of the Patient Focused Research and Advocacy Committee of the GBM-AGILE (Adaptive Global Innovative Learning Environment), a global trial to improve the survival of GBM patients with a global force of over 150 neurosurgeons, neuro-oncologists, pathologists, imagers, basic and clinical neuro scientists, from academic, industry, and government. She is a member of the Scientific Advisory Board of Medelis, Inc., an oncology CRO located in Fountain Hills, AZ. She also serves on the International Consulting Committee of the China National Research Center for Translational Medicine in Shanghai. Dr. Ba is a member of BayHelix, an invitation-only organization of leaders of Chinese origin in the global life sciences and healthcare community based in San Francisco with regional offices in Shanghai and Beijing.

Dr. Ba served on the Organizing Committee for the 2015 Personalized Medicine Conference, a cross-industry, cross-disciplinary panel made up of providers, payers, educators, researchers, and government agency representatives—all committed to personalized medicine. She served as a Past President (2010-2011) Board of Directors (2006-2013) and is currently a member of the Board of Advisors of the Chinese Biopharmaceutical Association–USA (Rockville, MD). In 2011, she was invited as one of a few business leaders to join Maryland Governor Martin O'Malley's Trade Mission to Asia and visited China, Korea, and Vietnam with Governor O'Malley. She also served on the Membership Committee of the International Union against Cancer (Geneva). Prior to joining NFCR, Dr. Ba was the Director of Chiral Chemistry and Fine Chemical Consulting Services at Technology Catalysts International (TCI) where she conducted market research, business evaluation, and competitive intelligence for an international clientele of major chemical and pharmaceutical companies. From 1991-1997, she was a Principal Research Chemist and then Project Manager of Technology Development and Research Planning at Arco Chemical Company (ARCO). Dr. Ba received her B.S. in radiochemistry from Peking University and her Ph.D. in chemistry from the University of Pennsylvania.

SPEAKER BIOGRAPHIES

Lynda Chin

Dr. Lynda Chin received her M.D. from the Albert Einstein College of Medicine in 1993, and is a board-certified dermatologist. She conducted her clinical and scientific training at Columbia Presbyterian Medical Center and the Albert Einstein College of Medicine where she served as Chief Resident of Dermatology. For the past 14 years, she has been a member of the Dana-Farber Cancer Institute and Harvard Medical School communities where she was Professor of Dermatology at the Harvard Medical School, member of the Department of Medical Oncology at Dana-Farber Cancer Institute, and a Senior Associate Member of the Broad Institute of MIT and Harvard. Dr. Chin also served as the Scientific Director of the Belfer Institute for Applied Cancer Science at the Dana-Farber Cancer Institute, and co-led the Dana-Farber / Harvard Cancer Center's Melanoma Program and the Harvard Skin SPORE.

In 2011, Dr. Chin joined The University of Texas MD Anderson Cancer Center where she is the Chair of the first-ever Department of Genomic Medicine, and is Scientific Director of the Institute for Applied Cancer Science. At the Broad Institute, Dr. Chin is principle investigator of the TCGA Genome Data Analysis Center.
Dr. Chin has made multiple scientific discoveries spanning the fields of transcription, telomere biology, mouse models of human cancer, oncogenomics, and personalized cancer medicine. She demonstrated the anti-neoplastic activity of the MAD family of repressors and co-discovered Sin3 co-repressor complex which provided the first link between sequence-specific transcription factors and modulators of chromatin architecture including class I histone deacetylase and N-CoR. Using the telomerase-knockout mouse, she conducted the first cancer studies which demonstrated that, in the p53 deficient setting, deactivated DNA damage signaling unleashes telomere-based crisis as a potent mutational mechanism in the development of cancer, a process that generates non-reciprocal translocations and copy number alterations of cancer-relevant loci.

Building on her successful effort to establish oligo-based array comparative genomic hybridization, Dr. Chin has championed comparative oncogenomics of mouse and human cancers and its integration with functional genomics to identify novel cancer genes. As a leader in translational genome medicine, she has enlisted these new cancer gene discoveries into productive drug discovery efforts in the Institute for Applied Cancer Science. Dr. Chin has developed function-based prognosis determinants, solving the longstanding clinical problem of identifying the subset of early stage melanoma patients who are hardwired for lethal progression, and opening the opportunity for adjuvant therapy for the first time.

In addition to her service on The Cancer Genome Atlas (TCGA) Executive Subcommittee, Dr. Chin is actively involved enabling the community to translate genome data via her establishment of 'disease working groups' that bring together genome scientists, biologists and clinicians in the broader community. She chairs two such groups – GBM and Melanoma Disease Working Groups. She is also a member of the Scientific Steering Committee of the International Cancer Genome Consortium. Dr. Chin co-founded AVEO Pharmaceuticals in 2002, a cancer biotechnology company that emphasizes cancer biology and genetics to identify new cancer targets with tumor maintenance roles. Most recently, Dr. Chin also founded Metamark Genetic, a cancer diagnostic company that will develop function-based prognostic determinants that can guide customized management of early-staged cancer patients including melanoma and prostate cancer.

COMPANY DESCRIPTIONS

Aethlon Medical is focused on addressing unmet needs in global health. The Aethlon Hemopurifier® is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier® depletes the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis and inhibit the benefit of leading cancer therapies. The Hemopurifier® is also an FDA designated "Breakthrough Device" related to the treatment of life-threatening viruses that are not addressed with approved therapies. Additionally, Aethlon owns 80% of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression.

Allevi, Inc. believes 3D tissues will have a huge impact on humanity and create an entire new industry. We help scientist print personalized patient tumor organoids unseen before in the lab. We have shipped our solutions to all corners of the globe. We are helping make personalized prognostics a reality.

Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company with products under development in oncology and autoimmune disease indications. The company's drug products use our proprietary recombinant human alpha fetoprotein (AFP) with unique immuno-oncology properties. ACT has exclusive worldwide rights to the targeted delivery platform Alpha Fetoprotein with over $100 million spent on the development of the in-licensed technology. Clinical studies of AFP have demonstrated safety in over 300 patients and established a robust Drug Master file with the FDA including manufacturing, toxicology, and human safety.

COMPANY DESCRIPTIONS

Aphios, is researching and developing anticancer therapeutics and supportive care drugs from medicinal plants and marine organisms based on the company's enabling technology platforms of drug discovery, manufacturing and delivery. Aphios' goal is to develop therapies to treat cancer as a chronic rather than acute disease, provide the less toxic and mostly plant-based natural drugs such as nanoformulations of Taxol® and Taxotere® that can be used in an acute setting until long-term preventative solutions can be developed, and to provide supportive care for cancer patients undergoing acute treatment.

Apricity Health's mission is to improve the quality and experience of care for both patients and their healthcare providers. Apricity Health has harnessed the knowledge and experience of the world's experts in cancer and IO therapy, adopted best practices in privacy and security to develop ApricityCare™ with advanced analytics, mobile and cloud technology. ApricityCare™ is an intelligent and interactive care pathway that: 1) facilitates early detection and timely intervention of irAEs by empowering patients and their clinical team with longitudinal monitoring and communication tools, and 2) disseminates best practices in irAE management by putting world-class expertise in the hands of practicing

Cambium Oncology LLC is a pre-clinical start-up founded early 2018 focused on the development and commercialization of novel immune-oncology therapeutics. The Company's lead compound has demonstrated significant improvement in survival rates in animal studies for pancreatic cancer, melanoma, leukemia and lymphoma. This compound also has potential for viral infection and auto-immunity. Cambium Oncology seeks a $10M Series A to fund a Phase I clinical trial for pancreatic cancer as its first application of one of 14 technologies licensed from Emory University and Georgia Tech.

COMPANY DESCRIPTIONS

Can Fite Biopharma's anti-cancer drug candidate Namodenoson is in Phase II clinical trial for the treatment of patients with advanced liver cancer. The drug is a small molecule orally bioavailable with an excellent safety profile and lack of hepatotoxicity. Drug proof of concept has been demonstrated in a former Phase I/II study. The drug targets the A3 adenosine receptor, highly expressed in cancer but not in normal body cells, with high affinity and selectivity. Data from the ongoing Phase II study are expected to be released in the next couple of weeks. Orphan and fast track status have been granted by FDA

Capella Therapeutics' lead drug candidate LL-191, for the treatment of non-small cell lung cancer and resulting brain metastasis, holds the potential to be a first-in-class drug for one indication and a best-in-class drug for another. LL-191 has clearly demonstrated superior efficacy over Tagrisso™ in eliminating brain metastases in several mice models. Additionally, LL-191 demonstrated great in vivo safety and tolerability, mainly resulting from a superior wild-type EGFR selectivity. In contrast to Tagrisso™ and other potential competitors who target one single resistant mutation only (EGFR T790M), LL-191 additionally targets resistant tumors driven by HER2 overexpression/amplification, which constitutes a second largest

CONCARLO Holdings, LLC, a pre-clinical stage drug development company, is committed to addressing unmet needs in oncology. Our first therapeutic candidate, IpY, is effective at inhibiting tumors in a variety of breast cancers. IpY disables the “on-off “switch that regulates cyclin-dependent kinases which are integral to tumor growth and metastasis.

COMPANY DESCRIPTIONS

Founded in 2013 and headquartered in Raleigh, North Carolina, FLAG Therapeutics, Inc is an early-stage oncology company focused on the development of therapies based on two investigational product platforms--the Anti-angiogenic & Anti-tubulin (AA/AT) platform and Purine Synthesis Inhibitor (PSI) platform - designed to harness the power of multiple therapeutic actions targeted by highly water-soluble small molecule compounds. Engineered to specifically overcome the shortcomings of conventional cancer therapies, namely efficacy, tolerability and drug resistance issues, FLAG's investigational compounds hold the potential to treat multiple cancer types, including brain, lung, ovarian, and pancreatic. To date, over $25 million in non-dilutive funding has been used to synthesize, optimize and screen compounds in vitro and in vivo, resulting in a library of thousands of promising compounds.

Geneius is a private biopharmaceutical company run by the Former CEO of Bluebird Bio focused on the discovery and clinical development of adoptive T cell therapy products that address the treatment of cancer and infections. The company has created a good manufacturing process, or GMP, for the production of T cells from peripheral blood for infusion into the patient, allowing for manufacturing at a price of 1/10th that of traditional CAR-T. Geneius' targeted DiversiTy™ platform is a novel ex vivo approach that re-educates T cells to become responsive to multiple, previously overlooked tumor antigens. Geneius' lead product candidate, GNS-TEBV-001, is currently in preclinical testing for EBV+, NHL, gastric and nasopharyngeal cancers. Geneius also has two additional products, GNS-TGBM-002 and GNS-TPC-003, in preclinical testing for glioblastoma and pancreatic cancer, respectively.

Genomic Expression is finding the best drug for the patient and the best patient for the drug by sequencing RNA. Analyzing RNA is able to tell if the tumor will respond to the new immune therapies, which is the only kind of therapy that is a potential cure. We entered into a strategic relationship with IBM to provide our analytics in a HIPAA compliment environment. Genomic Expression started as the diagnostic partner in the $32M Danish "Genome Denmark" project, and we have subsequent developed our platform with the goal of improving outcomes for cancer patients.

COMPANY DESCRIPTIONS

GLAdiator Biosciences is based upon a novel delivery platform that targets a foundational biological property of tumor cells, the exposure of phosphatidylserine (PS) on the surface of the tumor cell. Our novel delivery platform addresses existing challenges to antibody drug conjugates, cell penetrating peptides and the delivery of novel therapeutic formats - namely poor targeting and inefficient transport into the tumor microenvironment and tumor cells, leading to off target toxicity and suboptimal dosing. The target specificity for cell surface exposed PS and subsequent

Immix Biopharma, Inc. develops novel therapies for cancer patients. The company's products include Imx-110 which is a nanoparticle delivery vehicle, co-loaded with small doses of cytotoxin and a potent agent that has shown synergy with multiple cytotoxic agents, such as doxorubicin, paclitaxel, carboplatin, PD1 inhibitors, T Cell therapies, and radiation; and Imx-111 which is a targeted form of Imx-110. Further, the company develops multi-component drug candidates. Immix Biopharma, Inc. primarily caters to chemotherapy and immunotherapy-resistant patients.

Immunicom has leveraged the latest, cutting-edge clinical research in immune regulatory pathways and their role in cancer and autoimmune disease to develop a revolutionary immunotherapy platform (Immunopheresis™) for treating cancer and other terminal diseases through a BLOOD FILTERING DEVICE. We filter a patient's blood of "blocking proteins" released by cancer cells that suppress the immune system. Once these proteins are removed, the immune system naturally attacks the tumor and cancer. Immunicom is led by Amif Jafri, the Former Head of R&D of Cardinal Health. The company first target is STNFr.

COMPANY DESCRIPTIONS

Immunomic Therapeutics' was founded in 2005 with leading industry experts including scientific founder, Dr. J. Thomas August from John Hopkins (JHU) to advance its foundational vaccine technology platform, LAMP-vax ("LAMP"). LAMP is an intracellular protein that can act as an "immunological potentiator" when incorporated into nucleic acid vaccines. The LAMP signal sequences can direct the antigen / allergen chimeric protein to activate an important subset of T cells resulting in im-

ImmunSYS is a clinical stage immunotherapeutic drug and device company focused on the development of a new late stage metastatic prostate cancer therapy system. The ImmunSYS Phase I data is compelling in that the therapy has delivered a 35% complete response rate in very late stage metastatic prostate cancer patients. The complete responses have been durable, with the longest patient treated over 3.5 years ago and still disease-free. These Phase I results are even more impressive considering that prostate cancers have not responded well to any of the numerous published systemically administered immunotherapy studies completed to date. The Phase I study included treatment of some additional adenocarcinomas which also produced comparable results.

Incysus is a biotechnology company focused on delivering a novel off-the-shelf product for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, our technologyaddresses the challenges that immunotherapies face when targeting cold, low mutation cancers. Incysus received approval of an investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA) to test the safety and activity of an allogeneic donor γδ T cell infusion for cancer immunotherapy in a Phase I trial. Incysus continues to advance our novel Drug Resistant Immunotherapy (DRI) platform with the submission of its second IND filing with the FDA. Our unique DRI technology offers an elegant approach to immuno-oncology that deals with multiple mechanisms of tumor resistance and immunosuppression.

COMPANY DESCRIPTIONS

From a biopsy, LLTech's technology determines in 2 minutes and with accuracy of 96% or higher (published papers) if the cells are a benign tumor, malignant tumor, inflammation or normal cells. This avoids the delay of sending the sample to a lab and waiting days for a report. The time saved and ability to begin necessary treatment immediately can greatly benefit patients and reduce costs. LLTech is the only company able to create cellular activity data that identify cells types and enable machine learning automated diagnosis. This is very important for both personalized medicine (biopsy adequacy), surgery (margins) and drug development (monitoring of a drug efficacy on cells / tissue culture).

Lumicell is a technology leader in the field of image-guided cancer surgery. The company is developing a novel system that enables real-time detection of tumor tissue in patients so that no cancer cells are left behind during surgery. The company's LUM System has unprecedented ability to see and remove cancer cells remaining in the surgical cavity – beyond the margin of the specimen – and has the potential to significantly improve surgical outcomes and reduce healthcare costs by eliminating the need for repeat surgeries. Lumicell is investigating the LUM System in patients undergoing surgery for breast cancer, prostate cancer, colorectal, esophageal and pancreatic cancers. Additional future indications are planned to include surgeries for lung, ovarian, and brain cancers.

NuView Life Sciences is a biotechnology company based in Park City, Utah focused on precision cancer diagnostics and therapeutics improving patient outcomes and reducing healthcare costs. Applications in development include: a Positron Emission Tomography (PET) imaging agent for the in vivo diagnosis of breast and prostate cancer and an in vitro diagnostic kit that may be used for detecting shed prostate and bladder cancer cells in voided urine. US Radiopharmaceuticals, a subsidiary of NuView Life Sciences, has 85,000-square-feet of FDA-registered, cGMP medical isotope manufacturing and distribution facilities located in Denton, Texas.

COMPANY DESCRIPTIONS

Oncolize uses polymer-based technology that makes new formulation development simple, scalable and affordable. The Company's InGell-technology consists of biodegradable polymers, that are safe, easy to scale-up and easy to formulate with very different types of drugs: small molecule drugs, peptides, hormones, proteins and anti-bodies, from poorly soluble to highly soluble, with Molecular weights from 100D to 150kD, and loading from 0.01% up to 25% drug weight/volume. The products are easily injected through thin needles or cathters in any location. Upon injection, the formulation rapidly forms a stable matrix, resulting in the localized drug depot 'in situ – in seconds'. As the depot degrades, the stored drugs are slowly released into the surrounding tumor. OncoLize has full and exclusive licenses to the InGell-technology for several types of tumor diseases, and has selected a range of suitable oncology drugs, both generic and novel.

OTraces has developed patent-pending proteomic noise suppression techniques and cloud-based software that enhances blood test accuracy to levels well above the current industry norm. OTraces is planning to launch a prostate cancer blood test in the U.S. for active surveillance (AS) that would detect the molecular often progression from moderate to aggressive and life-threatening tumors often missed by PSA and other conventional approaches. The company has similar plans for AS tests both its prostate and breast cancer blood tests in China, subject to additional funding and collaboration with a suitable business partner most likely on a revenue-sharing basis.

OBT has created, to our knowledge, the only existing detailed molecular library of the cancer-immune cell interface (or synapse). We have used this to develop a number of exciting novel drugs targeting various subtypes of different solid and hematological cancers, including those refractory to conventional and existing IO treatments. OBT will commence shortly a US trial on one of its lead assets (currently in EU trials as well) in high risk breast cancer patients.

COMPANY DESCRIPTIONS

SageMedic is creating a 3D micro-tumor assay to help physcans determine the best cancer treatment for their patient. To do so, we take a live tumor biopsy, create hundreds of 3D micro-tumors, expose them to a wide range of anti-cancer drugs (e.g. chemotherapy or targeted therapy), and measure the response to identify the most effective treatment that will be communicated with the treating oncologist.

SciTech Development, LLC is a clinical stage, biopharmaceutical company that converted fenretinide, an underperforming yet proven anticancer agent, into a fully functional intravenous (IV) drug for the treatment of numerous cancers. SCI's clinical lead compound, ST-001, is a short-development track anticancer agent delivered in a novel nanoparticle-based system. Fenretinide has shown clinical, targeted cancer destroying activity and, when combined with SCI's new, patented, nanoparticle delivery system, promises to save many lives. Initially, it was clinically tested and shown to be safe in a breast cancer prevention trial of more than 3,000 women. It later evolved into a cancer therapeutic and was shown to be effective in treating many other cancers. Development of fenretinide was hindered by low active drug concentrations and by the side effects associated with poorly designed IV delivery systems. ST-001 overcomes those problems by delivering greater concentrations safely at the required dose levels. It will initially target T-cell lymphoma and small cell lung cancer followed by broader market opportunities that include leukemia, breast, ovarian, lung, pancreatic, prostate, renal cell and other cancers previously shown to respond to fenretinide.

SignPost - is at the very forefront globally - in the development of a molecular diagnostic test and screen for invasive breast cancers. SignPost can detect all invasive breast cancers, including all subtypes, and all stages from 1 thru 4., The accuracy of SignPost is greater than 99% (for both sensitivity and specificity).

COMPANY DESCRIPTIONS

Sonify Biosciences is building a device to gently heat and treat many kinds of cancer. This gentle heat is a kind of thermal therapy called hyperthermia, currently used in clinic to re-sensitize inoperable tumors to chemotherapy and radiation therapy. Despite decades of research, positive patient outcomes, and existing billing and Medicare reimbursement codes, less than 1% of eligible patients receive this lifesaving treatment because currently available devices have not met clinicians' needs. Sonify uniquely combines well-understood technologies in one affordable, accurate, and noninvasive user-friendly package, redefining the state of the art of hyperthermia devices.

SynDevRx is the first mover in the emerging field of metabo-oncology - the cancer patient population defined by the nexus of cancer and obesity/ metabolic dysfunction. Cancer patients with obesity or metabolic complications like T2D have more aggressive cancer and die faster. Further, obesity reduces the effectiveness of standard treatments (chemotherapy, immunotherapy, targeted). Over 10 types of cancer are effected by metabolic dysfunction, making this a multi-billion dollar opportunity. SDX is the first-mover with a novel drug (SDX-7320) to treat these patients. SDX-7320 has clinical data in late-stage cancer patients showing strong supporting biologic activity (anti-tumor, anti-metabolic) in a Phase 1 clinical trial. SDX-7320 is protected with 12 granted patents (composition of matter and methods).

"Veriskin is a medical device company dedicated to facilitating and improving the accuracy of skin cancer screening. Uncertainty in the initial assessment by non-specialist caregivers leads to failure to detect skin cancer at an early, more treatable stage, hundreds of malpractice claims due to false negative diagnoses and many unnecessary specialist referrals and biopsies. Overall, the lack of accurate, objective assessment tool for frontline caregivers leads to preventable loss of lives and costs the healthcare system more than $3B each year. The TruScore device is a proprietary, non-invasive, low-cost (COG<$250), hand-held unit that aids a non-expert user to rapidly (~2 min) and objectively determine whether a suspect skin lesion is cancerous, reducing the number of false negatives and eliminating unneeded escalation of care and biopsies. The patent pending technology works by detecting and analyzing force-induced hemodynamic abnormalities due cancer-induced angiogenesis which is a well-established hallmark of cancer. VeriSkin has developed a proprietary AI algorithm and protocols to achieve unparalleled screening accuracy in differentiating skin cancer from a variety of benign conditions. Pilot clinical studies performed in multiple dermatology clinics have demonstrated sensitivity of ~100% and specificity of 96.7% in screening for any

COMPANY DESCRIPTIONS

Zomanex is a venture-backed Corporation focused on developing and commercialising of our innovative patent-protected technology, ORAZOM. ORAZOM is an enabling platform technology that improves the solubility and permeability of Biopharmaceutical Classification System (BCS) Class II (low soluble/high permeable) drugs and BCS Class IV (low soluble/low permeable) drugs. BCS Class II drug examples include Atorvastatin (Lipitor), Imatinib (Gleevec) and Ciprofloxacin (Cipro), to name a few, and BCS Class IV drug examples include Paclitaxel (Taxol), Ritonavir (Norvir) and Abiraterone (Zytiga), to name a few. To date, ZOMANEX has identified 60 drugs (40 Class II and 20 Class IV) that can be placed on the ORAZOM platform and has already successfully produced 4 products, namely, BCS Class II Amiodarone and Spironolactone plus Class IV Paclitaxel and Cyclosporine A.

REGISTERED INVESTORS—OCT 2018

1812 Ventures
3e Bioventures
AIM-HI / National Foundation for Cancer Research
AKS Family Partners
Alpha Square Group
Aisling Capital
AltaCap
Anup Singh (individual investor)
Aranmore Advisors
ARD Healthcare
Band of Angels
BioSense Global
Blue Ox (Family Office)
Boler Biotech
Business Development Bank of Canada
Canadian Innovation Lab
Cancer Prevention and Research Institute of Texa
Cancer Research Institute
Canepa Healthcare
Chaperone Investment
Clemente Advisors, LLC
Cross Road Biotech Inversiones Biotecnológicas
Dabar Investment Associates
Dandrew Partners
Dartmouth Ventures
Easton Capital
Edelson Technology Partners
Ellington Healthcare Partners
Enso Ventures
Esousa
Excelyrate Capital
First Round Capital
Fortress Biotech
Fortunatus Capital
Gonzalez Family Office
Gore Range Capital
GCF Family Office
GSK - SR One Fund
Guardian Life - GIS Strategic Ventures
Harald Duell - Private Investor
Health Catalyst Capital LP
Healthbox (Intermountain Health VC Fund)
HI Investors
HJ Capital
iLab Ventures (LEO Pharma's Digital Health VC)
iNetworks Opportunity Fund
Innogest Capital
International Cancer Impact Fund
Intrinsic Value Capital
Jina Ventures
JZ Capital / Jordan Family Office
Kingdon Foundation
Landmark Family Office
LEAF Single Family Office
Leukemia and Lymphoma Society - Therapy Acceleration Program (LLS)
LifeTech Capital
LLEX Partners
LSWorks
Lymo Ventures
MaidStone Life Sciences
Mass Medical Angels
MedPro Investors
Merck - Global Health Innovation Fund (GHI)
Monarch Holdings
Murdock Capital
Northern Light Venture Capital
NSIP LLC
Oakdene Capital
Park Avenue Capital
PBM Capital
Pfizer
Prevail Partners
Purdue Pharma / Greenfield Bioventures / Sackler FO
Remiges Ventures
Samsung Corporation
Sandbox (Blue Cross/Blue Shield's Venture Capital Fund)
Santé Ventures
Skylight Investment
Silicon Valley Ventures Growth Partners LLP
Sound Affects
Touchdown Ventures
Two Sigma Ventures
Verena Capital
Vista Capital Advisors

RECENT CONFERENCES

10th Annual OneMedForum @ JPM

January 2018

San Francisco, CA

Altru Oncology and Women's Health Conferences @ World Economic Forum

January 2018

Klosters & Davos, Switzerland

NYC Oncology Investor Conference

May 2018

New York, NY

FUTURE CONFERENCES

Altru Oncology and Impact Conference @ World Economic Forum

January 2019

Klosters & Davos, Switzerland

Boston Oncology Investor Conference

March 2019

Boston, MA

NYC Oncology Investor Conference

May 2019

New York, NY

Oncology Track—China BioMed

September 2019

Suzhou, China